Fluticasone Inhalation

Introduction Overview

Generic Name

fluticasone inhalation

Brand Name

Flovent HFA

Dosage Form

Aerosol inhaler (metered-dose inhaler)

Drug Class

Inhaled corticosteroids

Pharmacokinetics

Absorption:
Fluticasone propionate administered via inhalation in Flovent HFA is delivered as a fine aerosol spray that deposits primarily in the lungs. Upon inhalation, the drug is quickly deposited in the airway mucosa, where it exerts its local anti-inflammatory effects. Systemic absorption occurs mainly via the lungs, with a bioavailability estimated to be approximately 10 to 20%, as the swallowed portion undergoes extensive first-pass metabolism in the liver, resulting in negligible systemic exposure from gastrointestinal absorption. The onset of action is not immediate; therapeutic effects on airway inflammation typically require several days of regular administration. Factors such as inhaler technique, the presence of airway obstruction, and concurrent pulmonary diseases can influence absorption efficiency.

Distribution:
Following absorption into systemic circulation, fluticasone propionate exhibits a high plasma protein binding (>99%), primarily to albumin. The volume of distribution is low to moderate, indicating limited distribution beyond the plasma and lung tissues. Because of its high lipophilicity, fluticasone concentrates in lung tissues to exert localized effects. It has minimal penetration into the central nervous system due to its physicochemical properties and active efflux by P-glycoprotein transporters. The high affinity of fluticasone for the glucocorticoid receptor in pulmonary tissues ensures its efficacy with localized action, minimizing systemic exposure and adverse effects.

Metabolism:
Fluticasone propionate undergoes extensive hepatic metabolism primarily via the cytochrome P450 3A4 (CYP3A4) enzyme system. The main metabolic pathway is through oxidative metabolism producing inactive metabolites, including 17β-carboxylic acid derivative and others that have no significant glucocorticoid activity. Because of this extensive first-pass metabolism, the oral bioavailability is negligible, reducing the risk of systemic corticosteroid side effects. Any drug interactions that inhibit CYP3A4, such as ketoconazole or ritonavir, may elevate systemic concentrations of fluticasone, increasing the risk of systemic corticosteroid effects.

Elimination:
Metabolites of fluticasone propionate are primarily eliminated via the feces, with less than 5% of the dose excreted in urine, predominantly as metabolites. The elimination half-life after inhalation is approximately 7.8 hours, although systemic levels often remain low due to rapid metabolism and predominant local action in the lungs. The inhaled route results in lower systemic corticosteroid exposure compared to oral corticosteroids, minimizing adrenal suppression risk. Renal or hepatic impairment can potentially alter metabolism and elimination, so clinical monitoring is warranted in such patients.

Dosage Forms

Available Dosage Forms:
Flovent HFA is provided as a metered-dose inhaler (aerosol) that delivers fluticasone propionate in a pressurized canister. The inhaler contains a suspension for oral inhalation as a fine spray delivered via a pressurized metered-dose inhaler device. Typical available strengths for Flovent HFA include 44 mcg, 110 mcg, and 220 mcg per actuation (inhalation).

Dosages for Adults and Adolescents:
The recommended starting doses vary depending on asthma severity and prior treatment. Adults and adolescents (12 years and older) generally begin with 88 mcg to 220 mcg twice daily via the inhaler. Dose escalation may be required based on clinical response to a maximum of 880 mcg twice daily in severe cases under medical supervision. Dose titration should balance symptomatic control with minimizing side effects.

Specific Patient Populations:
Children as young as 4 years may be treated with fluticasone inhalation preparations; however, dosing is typically lower. Flovent HFA safety and efficacy for children involve doses ranging from 88 mcg twice daily, adjusted as needed. Elderly patients may require careful dose adjustment due to potential comorbidities. Patients with hepatic impairment should be monitored closely because of metabolism through CYP3A4. Use in pregnancy should be approached cautiously, weighing asthma control benefits versus potential fetal risks.

Clinical Guidelines:
Flovent HFA is intended for regular maintenance therapy of asthma and is not a rescue medication. Use of a spacer device is recommended to improve delivery and reduce oropharyngeal deposition. Proper inhaler technique is critical for optimal dosing. Patients should rinse their mouth after use to prevent local side effects such as oral candidiasis.

Mechanism Of Action

Fluticasone propionate, the active component of Flovent HFA, is a synthetic trifluorinated corticosteroid with potent glucocorticoid activity. It acts primarily by binding with high affinity to intracellular glucocorticoid receptors (GR) present in the cytoplasm of target cells, especially those in the airway epithelium and inflammatory cells such as eosinophils, mast cells, and T lymphocytes. Upon ligand binding, the receptor-steroid complex translocates to the nucleus where it modulates gene transcription by binding to glucocorticoid response elements (GREs), enhancing the expression of anti-inflammatory proteins (e.g., lipocortin-1) and repressing pro-inflammatory gene expression.

This genomic mechanism reduces the production and release of inflammatory mediators including cytokines (IL-4, IL-5, IL-13), chemokines, prostaglandins, leukotrienes, and histamines. Consequently, the recruitment and activation of inflammatory cells are suppressed, decreasing airway inflammation, hyperresponsiveness, edema, and mucous hypersecretion characteristic of asthma pathophysiology. Fluticasone's anti-inflammatory action reduces airway remodeling and bronchial hyperreactivity triggered by allergens or irritants.

In addition to genomic effects, there are non-genomic effects including modulation of membrane-bound receptors and ion channels, promoting rapid anti-inflammatory responses. The drug also decreases vascular permeability, preventing edema and narrowing of airways.

Compared to other inhaled corticosteroids, fluticasone propionate has a high receptor affinity, long tissue retention in the lungs, and extensive first-pass metabolism that minimizes systemic exposure, providing a favorable therapeutic index. Clinical trials have demonstrated its efficacy in reducing asthma exacerbations, improving lung function (e.g., FEV1), and decreasing reliance on rescue beta-agonists. Research also highlights its utility in both mild and severe persistent asthma as a cornerstone in asthma maintenance therapy.

Pharmacological Actions

Potent anti-inflammatory activity via glucocorticoid receptor agonism
Suppression of airway eosinophilic inflammation
Reduction of airway mucosal edema and hyperresponsiveness
Inhibition of cytokine and chemokine production by inflammatory cells
Decreased recruitment and activation of mast cells, T-lymphocytes, and macrophages
Reduction of mucus secretion by airway epithelial cells
Stabilization of vascular membranes reducing capillary permeability
Improvement of airway caliber and reduction of bronchospasm frequency
Enhancement of beta-2 adrenergic receptor responsiveness on airway smooth muscle
Decreased frequency and severity of asthma exacerbations
Local immunosuppressive effects minimizing airway hyperreactivity
Minimal systemic corticosteroid activity when inhaled at therapeutic doses
Long pulmonary tissue retention leading to sustained anti-inflammatory effect
Rapid non-genomic effects modulating membrane receptor activity
Inhibition of airway remodeling processes in chronic asthma

Therapeutic Or Clinical Uses

Maintenance treatment of asthma in adults and children 4 years and older
Prevention of asthma attacks and reduction of airway inflammation
Adjunctive therapy in combination with oral corticosteroids for severe asthma
Management of persistent bronchial asthma requiring daily corticosteroid therapy
Control of symptoms associated with chronic inflammation of the airways
Reduction of frequency and severity of asthma exacerbations
Maintenance therapy post-acute asthma exacerbation recovery
Improvement of lung function parameters such as FEV1 and peak expiratory flow
Reducing the need for short-acting beta-2 agonists for rescue treatment
Use in patients poorly controlled with beta-agonists alone
Treatment option in patients with exercise-induced bronchospasm prevention
Off-label use in eosinophilic airway inflammation under specialist guidance
As part of a stepwise asthma management protocol as per GINA guidelines
Treatment to minimize corticosteroid systemic exposure compared to oral steroids
Pediatric use for chronic asthma control with appropriate dosing adjustments

Side Or Adverse Effects

Hoarseness and dysphonia due to local corticosteroid effects on vocal cords
Oropharyngeal candidiasis (thrush) presenting as white patches or soreness
Cough, throat irritation, and dry mouth following inhalation
Headache and nasal congestion commonly reported
Nausea, vomiting, and upset stomach in some patients
Potential for systemic corticosteroid effects with high doses or prolonged use
Blurry vision, tunnel vision, or eye pain indicating possible glaucoma or cataracts
Worsening of asthma symptoms or paradoxical bronchospasm after inhalation
Possible adrenal suppression and reduced cortisol production with chronic use
Risk of growth suppression in pediatric patients with long-term therapy
Skin rash or hypersensitivity reactions including hives and swelling
Potential for blood vessel inflammation presenting with systemic symptoms
Liver function abnormalities including jaundice in rare cases
Fatigue, weakness, and symptoms consistent with steroid withdrawal if stopped abruptly
Rare but serious allergic reactions including anaphylaxis

Precautions

Do not discontinue Flovent HFA abruptly; tapering may be necessary to avoid adrenal insufficiency
Rinse mouth after each use to reduce risk of oral candidiasis and maintain dental hygiene
Use with caution in patients with active or quiescent infections, including tuberculosis
Monitor for signs of glaucoma or cataracts during long-term therapy
Assess growth regularly in pediatric patients receiving chronic inhaled corticosteroids
Avoid exposure to chickenpox or measles due to increased risk of severe infection
Use caution and assess for potential drug interactions that may increase systemic steroid levels
Avoid use during acute asthma attacks; Flovent HFA is not a rescue medication
Inform healthcare provider if pregnant or breastfeeding to evaluate risk-benefit balance
Use lowest effective dose to maintain asthma control and minimize systemic exposure
Monitor patients with hepatic or renal impairment closely for altered drug metabolism
Educate patients on correct inhaler technique to optimize drug delivery and efficacy
Advise patients to seek immediate medical attention if severe allergic reactions occur
Evaluate bone mineral density in patients with risk factors for osteoporosis
Ensure regular follow-up to monitor asthma control and adjust therapy as needed

Warnings

Flovent HFA is not to be used as a rescue therapy during acute bronchospasm or asthma attacks
Long-term use may increase risk of systemic corticosteroid effects including adrenal suppression
Inhalation powder formulations contain lactose; contraindicated in patients with milk protein allergy
Sudden discontinuation can lead to worsening of asthma control and adrenal crisis
Use with caution in patients susceptible to infections, as corticosteroids suppress immune response
Risk of growth retardation in children and adolescents necessitates careful dose monitoring
May cause glaucoma, cataracts, or increased intraocular pressure on prolonged use
Patients should avoid exposure to chickenpox or measles unless immunized or prophylaxis given
High doses or concomitant use with CYP3A4 inhibitors can increase systemic corticosteroid effects
Monitor for paradoxical bronchospasm which can be life-threatening
Concurrent use with other corticosteroids can lead to additive systemic effects
Do not use Flovent HFA if known hypersensitivity to fluticasone or any formulation components
Can mask signs of infection; vigilance required during immunosuppressive treatment
Storage warnings: keep away from heat or flame, canister may explode if exposed to high temperature
Use caution in patients with pre-existing osteoporosis or other bone diseases

Contraindication

Known hypersensitivity to fluticasone propionate or any inhaler excipients
Allergy to milk proteins in patients using lactose-containing inhalation powder formulations (Flovent Diskus, ArmonAir, Arnuity Ellipta)
Use as sole therapy during acute asthma attacks or status asthmaticus
Patients with untreated fungal, bacterial, systemic viral, or parasitic infections
Known severe hypersensitivity reactions to inhaled corticosteroids
Patients with active tuberculosis of the respiratory tract without appropriate treatment
Use in patients with acute respiratory infections until resolved
Avoid use in patients with glaucoma or cataracts without monitoring
Contraindicated to use in children below 4 years of age for Flovent HFA (other fluticasone formulations vary)
Concurrent administration with potent CYP3A4 inhibitors should be avoided due to risk of elevated systemic exposure
Not indicated for relief of sudden bronchospasm symptoms
Patients with hypersensitivity to metered-dose inhaler propellants (although rare)
Known intolerance to corticosteroids of any type
Patients who cannot perform inhalation maneuvers properly without assistance
Individuals with hypersensitivity reactions to tris buffer or other excipients in the inhaler device

Drug Interactions

Potent CYP3A4 inhibitors such as ketoconazole, ritonavir, and itraconazole can increase systemic fluticasone levels, enhancing risk of corticosteroid side effects
Concomitant use with other systemic corticosteroids may cause additive suppression of adrenal function
Use with caution alongside immunosuppressants or antifungal agents due to overlapping toxicities
Interactions with beta-2 agonists may require monitoring for enhanced or diminished bronchodilator response
Certain antiretroviral drugs can increase plasma corticosteroid concentrations, necessitating dose adjustments
Drugs that induce CYP3A4 enzymes (e.g., rifampin, carbamazepine) can reduce fluticasone effectiveness
Co-administration with diuretics can increase risk of hypokalemia
Potential interaction with CYP3A4 inhibitors increasing risk for Cushing’s syndrome or adrenal suppression
Caution when used with nasal decongestants or other inhaled corticosteroids to avoid additive adverse effects
Some antibiotics may affect steroid metabolism; close monitoring recommended
Herbal products such as St. John's Wort may reduce fluticasone plasma concentrations
Concurrent use with strong antifungal or antiviral agents may alter fluticasone pharmacokinetics
Interactions that alter liver enzyme activity can significantly impact drug efficacy and safety
Patients should inform healthcare providers of all prescription, OTC, and herbal medications due to possible interactions
No significant interaction expected with antacids, but gastrointestinal conditions may affect inhaler use

Preparations Of The Drug

Flovent HFA metered-dose inhaler delivering 44 mcg, 110 mcg, and 220 mcg per actuation
Flovent Diskus - dry powder inhaler containing fluticasone at various dosages
Arnuity Ellipta - dry powder inhaler with fluticasone furoate variant
ArmonAir Digihaler - digital dry powder inhaler with integrated dose counter
ArmonAir RespiClick - lactose-containing dry powder inhaler
Flovent Rotadisk - another dry powder inhalation device with fluticasone formulation
Oral corticosteroid preparations separate from inhaled formulations; used adjunctively in severe cases
Combination inhalers containing fluticasone with long-acting beta-agonists (e.g., fluticasone/salmeterol)
Nebulized fluticasone formulations are not currently available; inhalation exclusively via inhalers
Spacer devices compatible with Flovent HFA to enhance pulmonary delivery
Multi-dose canisters with integrated dose counters for patient convenience and adherence
Inhaler devices calibrated for consistent fluticasone dose delivery per actuation
Packaged with detailed instructions to ensure proper inhalation technique
Storage containers designed to protect against moisture and temperature extremes
Available through prescription only, with dosing adjusted by healthcare professionals